MAIA Biotechnology (MAIA) Receivables - Other (2021 - 2025)
MAIA Biotechnology (MAIA) posted quarterly Receivables - Other of $82685.0 for Q3 2025, up 54.24% year-over-year from $53608.0 in Q3 2024, and up 0.5% quarter-over-quarter from $82272.0 in Q2 2025.
MAIA Biotechnology (MAIA) Receivables - Other (2021 - 2025) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Receivables - Other for 5 consecutive years, with $82685.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Receivables - Other rose 54.24% year-over-year to $82685.0; the TTM figure through Sep 2025 stood at $82685.0 (up 54.24% YoY), while the FY2024 annual figure was $77347.0, down 46.54% from the prior year.
- Receivables - Other rose to $82685.0 in Q3 2025 per MAIA's latest filing, from $82272.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $386825.0 in Q2 2023 and bottomed at $43666.0 in Q4 2021.
- Historically, Receivables - Other has averaged $167125.4 across 5 years, with a median of $144680.0 in 2023.
- Annual changes were most pronounced in 2022 — Receivables - Other jumped 593.42% — and 2024, when it tumbled 55.23%.
- MAIA Biotechnology's Receivables - Other stood at $43666.0 in 2021, then surged by 593.42% to $302789.0 in 2022, then tumbled by 52.22% to $144680.0 in 2023, then plunged by 46.54% to $77347.0 in 2024, then climbed by 6.9% to $82685.0 in 2025.
- Business Quant data shows MAIA's Receivables - Other at $82685.0 in Q3 2025, $82272.0 in Q2 2025, and $78084.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 82,685.00 |
| Sep 30, 2025 | 82,685.00 |
| Jun 30, 2025 | 82,272.00 |
| Jun 30, 2025 | 82,272.00 |
| Mar 31, 2025 | 78,084.00 |
| Mar 31, 2025 | 78,084.00 |
| Dec 31, 2024 | 77,347.00 |
| Dec 31, 2024 | 77,347.00 |
| Sep 30, 2024 | 53,608.00 |
| Sep 30, 2024 | 53,608.00 |
| Jun 30, 2024 | 177,687.00 |
| Jun 30, 2024 | 177,687.00 |
| Mar 31, 2024 | 155,969.00 |
| Mar 31, 2024 | 155,969.00 |
| Dec 31, 2023 | 144,680.00 |
| Dec 31, 2023 | 144,680.00 |
| Sep 30, 2023 | 114,426.00 |
| Sep 30, 2023 | 114,426.00 |
| Jun 30, 2023 | 386,825.00 |
| Jun 30, 2023 | 386,825.00 |